Mumbai/UNI: Glenmark Pharmaceuticals Inc, USA has been granted final approval by the United States Food & Drug Administration (U.S. FDA) for Fingolimod Capsules, 0.5 mg, the generic version of Gilenya Capsules, 0.5 mg, of Novartis Pharmaceuticals Corporation.
According to IQVIATM sales data for the 12 month period ending April 2020, the Gilenya Capsules, 0.5 mg market2 achieved annual sales of approximately 2.1 billion dollars, a company statement said on Friday.
Glenmark’s current portfolio consists of 164 products authorized for distribution in the US marketplace and 44 ANDA’s pending approval with the US FDA.
In addition to these internal filings, Glenmark continues to identify and explore external development partnerships to supplement and accelerate the growth of its existing pipeline and portfolio.
Support Our Journalism
We cannot do without you.. your contribution supports unbiased journalism
IBNS is not driven by any ism- not wokeism, not racism, not skewed secularism, not hyper right-wing or left liberal ideals, nor by any hardline religious beliefs or hyper nationalism. We want to serve you good old objective news, as they are. We do not judge or preach. We let people decide for themselves. We only try to present factual and well-sourced news.
